Navigation Links
Green Beans for Cancer Prevention and Treatment.

It is well known that eating green vegetables, beans, nuts, cereals and fruits prevents cancer, now it is found that beans and wheat bran contains an enzyme inhibitor Inositol // pentakisphosphate which is found to have anti-cancer effects by blocking the action of enzyme Phosphoinositide 3 kinase.

Dr. Marco Falasca and colleagues from the University College London has reported the results of their study in Cancer Research Journal in which they had said that the natural green foods we eat contains anti-cancer compounds which prevents cancer occurrence. The Inhibitor Inositol pentakisphosphate was isolated from the legumes by the scientists and was found to inhibit the enzyme Phosphoinositide 3 kinase in mice model, in which they found that the inhibitors reduced the tumor growth in ovarian and lung cancer. The inhibitor also had the ability to enhance the activity of other cancer therapy drugs. Scientists as to develop inhibitor compound Inositol pentakisphosphate chemically so that required concentration can be had by the humans for cancer prevention and treatment, as chemical stability of the compounds are very fragile and can be toxic, so an effective chemical compound of Inositol has to be developed which blocks the enzyme effectively.

Dr Falasca said: "Our study suggests the importance of a diet enriched in foods such as beans, nuts and cereals which could help prevent cancer.”Our work will now focus on establishing whether the phosphate inhibitor can be developed into an anti-cancer agent for human therapy. "We believe that Inositol pentakisphosphate is a promising anti-cancer tool and we hope to bring it to clinical testing soon."

Henry Scowcroft of Cancer Research UK said: "It is always encouraging when a newly discovered chemical is shown to have anti-cancer activity in the laboratory, especially when it occurs naturally in foods like beans and peas. "Obviously, the next step is to look at whether inositol pentakisphosphat
'"/>




Page: 1 2

Related medicine news :

1. Green tea beneficial in preventing osteoarthritis
2. Eating Greens fights cancer
3. Green Onions Blamed in Outbreak
4. Green Tea Might Help Patients With Prostate Cancer
5. Yet Another Use For Green Tea Extract
6. Exposure To Greenery And Graffiti May Affect Obesity
7. Can Green Tea Prevent Alzheimers?
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Polyphenols in Green Tea Cause Liver Damage At High Doses
10. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
11. Green Light From EU To Poultry Farmers
Post Your Comments:
(Date:5/16/2008)... report side effects, but critics want agency to a...ealthDay News) -- Direct-to-consumer drug ads on t...that would allow consumers to report adverse side ..., The experts serve on a panel that advises the U....s are already mandated by the FDA for print ads. A...
(Date:5/16/2008)...eing presented at the American Society of Clinical... change treatment practice in about 25 percent of ...oposed changes to the way colorectal cancers will ...ncer Institute (NCI) SEER population-based statist...nical trial data, shows that outcomes of patients ...
(Date:5/16/2008)...s located just beneath the lining of the uterus (s...ial cavity after uterine artery embolization (UAE)...ding to a new study. , The study included 49 pa...ination before and after UAE. The study found that...ed to the endometrial cavity after UAE, said Sachi...
(Date:5/16/2008)... Cast Scheduled for May 19 at 10:15 a.m. Eastern T...esponse Biomedical,Corporation (TSX: RBM, OTCBB: R...cutive Officer, is scheduled to present at the Rod...nce on Monday May 19th at 10:15 a.m.,EDT., A live... the Company,s,Web site at, http://www.responsebio...
Breaking Medicine News(10 mins):Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
... expression of therapeutic genes, which will have ... presented today at the 10th Annual Meeting of the...e. Carefully regulating gene expression is crucia...erapy. For many applications, gene transfer is bei...
...nts with obstructive sleep apnea (OSA) have higher... from the lining (endothelium) of their blood vess...ho do not have OSA. The finding may help explain w... for cardiovascular disease (CVD). According to t...
...ulin gene to diabetes patients using nanoparticles...of the American Society of Gene Therapy (ASGT) in ... autoimmune destruction of the insulin producing p...e loss of insulin, blood sugar levels rise too hig...
...n could help treat people who are suffering from s...g to traditional treatment. Thomas Schlaepfer, pr...ity Hospital in Bonn, Germany and associate profes...at Johns Hopkins University School of Medicine in ...
Other Medicine News:Health News:New Platform for Regulating Expression of Therapeutic Genes Unveiled 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3Health News:Novel Delivery Method of Insulin Gene to Combat Juvenile Diabetes Developed 2Health News:Implanting Electrodes in the Brain Could Help Treat Severe Depression 2
(Date:5/16/2008)...e/ -- Data from three studies,evaluating associati...vels,and the rate of blood transfusions, as well a...ment for erythropoiesis-stimulating agents (ESAs),... will be presented at the,American Society of Clin...th. The meeting will take place in Chicago from Ma...
(Date:5/16/2008)...PEGylation of a Small Molecule with ..., Calif., May 16 /- Nektar,...sults today from a Phase 1,study of NKTR- 102, PEG...-tumor activity in patients with refractory solid ...small molecule PEGylation technology,produced an i...
(Date:5/16/2008)...ay Offer Novel Approach to Blood .../- Pharmacopeia (Nasdaq:,PC... of novel small,molecule therapeutics, announced t... Receptor Antagonist (DARA), showed statistically ...a study in patients with mild to,moderate hyperten...
(Date:5/15/2008)...wire/ -- Eisai Corporation of North,America announ...acts about,compounds in the company,s oncology pip...research have been accepted for presentation at th...linical Oncology (ASCO),taking place in Chicago f...stracts on Eisai marketed products and,investigati...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Convera 28R 29 and Canon Communications Launch PharmaLiveSearch com 11492 1Convera 28R 29 and Canon Communications Launch PharmaLiveSearch com 11492 2Convera 28R 29 and Canon Communications Launch PharmaLiveSearch com 11492 3General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 1General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 2General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 3General Atlantic and Hellman 26 Friedman Purchase HLTH Corporations Remaining Interest in Emdeon 11489 4Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3177 1Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3177 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3177 3Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 1Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 2Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 3
...anespimycin Shown to Have No Effect on QTc Interva... Kosan,Biosciences Incorporated today presented sa... its lead Hsp90 inhibitor,tanespimycin (KOS-953)....ents was conducted in four Phase 1 trials of tanes...d in more than 85,patients. Tanespimycin was found...
...AWRENCEVILLE, N.J.--(BUSINESS WIRE)--Apr 16, 2007 ...presentation of several,scientific studies relatin...nnual Meeting of the American Association for Canc... Los Angeles,California. During this meeting, on ...ientific founder of Onconova was honored as,the re...
Other Medicine Technology:Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 2Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 3Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 4Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles 2Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles 3
Straight shafts with extra fine pointed tips and 6mm tying platform. Smooth handle with dull finish/
A necessary addition to any Trial Lens set, the Reichert Trial Frame provides a comfortable fit and smooth controls for quick, easy lens fitting.,The robust design, high-quality materials, and p
... of the most competitively priced chair and stand ...odern ergonomic design, contemporary styling, or t...Advantage manual recline chair meets the needs of ... in patient comfort and ease of use. The counterba...
...ombines the traditional features you would expect,...ion and cord-free battery power.,The cool-run... clear green illumination target, and virtually ma...d completely cordless, the ML1 Manual Lensometer g...
Medicine Products: